JP2020533965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533965A5 JP2020533965A5 JP2020508320A JP2020508320A JP2020533965A5 JP 2020533965 A5 JP2020533965 A5 JP 2020533965A5 JP 2020508320 A JP2020508320 A JP 2020508320A JP 2020508320 A JP2020508320 A JP 2020508320A JP 2020533965 A5 JP2020533965 A5 JP 2020533965A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000009824 affinity maturation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546336P | 2017-08-16 | 2017-08-16 | |
| US62/546,336 | 2017-08-16 | ||
| US201762582609P | 2017-11-07 | 2017-11-07 | |
| US62/582,609 | 2017-11-07 | ||
| PCT/EP2018/072272 WO2019034753A1 (en) | 2017-08-16 | 2018-08-16 | ANTIBODY CD38 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533965A JP2020533965A (ja) | 2020-11-26 |
| JP2020533965A5 true JP2020533965A5 (https=) | 2021-09-24 |
| JP7299873B2 JP7299873B2 (ja) | 2023-06-28 |
Family
ID=63259520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508320A Active JP7299873B2 (ja) | 2017-08-16 | 2018-08-16 | Ｃｄ３８抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11236173B2 (https=) |
| EP (1) | EP3668543A1 (https=) |
| JP (1) | JP7299873B2 (https=) |
| KR (1) | KR102770110B1 (https=) |
| CN (1) | CN111032086B (https=) |
| AU (1) | AU2018316522B2 (https=) |
| CA (1) | CA3072296A1 (https=) |
| SG (1) | SG11202000484TA (https=) |
| WO (1) | WO2019034753A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| US12310965B2 (en) | 2019-03-29 | 2025-05-27 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2021003074A1 (en) | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
| US12181485B2 (en) | 2020-09-10 | 2024-12-31 | CASI Pharmaceuticals, Inc | Methods of blood screening |
| CN112300281B (zh) * | 2020-10-29 | 2021-06-11 | 杭州爱唯生命科技有限公司 | 含有nk细胞的药物组合物及其治疗癌症的用途 |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| WO2025213286A1 (zh) * | 2024-04-07 | 2025-10-16 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| AU2011202520C1 (en) | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| AU2016228249A1 (en) | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| AU2013209322A1 (en) | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| CN101605906A (zh) | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| KR20090088946A (ko) | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | 씨디70에 결합하는 인간 항체 및 이의 용도 |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| AU2009301580B2 (en) | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| EP2970471A2 (en) | 2013-03-15 | 2016-01-20 | F. Hoffmann-La Roche AG | Anti-crth2 antibodies and their use |
| JP6775422B2 (ja) * | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| WO2016089862A1 (en) | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| ES2927119T3 (es) * | 2015-04-08 | 2022-11-02 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CD38 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| US12590171B2 (en) | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
-
2018
- 2018-08-16 AU AU2018316522A patent/AU2018316522B2/en active Active
- 2018-08-16 KR KR1020207003078A patent/KR102770110B1/ko active Active
- 2018-08-16 SG SG11202000484TA patent/SG11202000484TA/en unknown
- 2018-08-16 JP JP2020508320A patent/JP7299873B2/ja active Active
- 2018-08-16 WO PCT/EP2018/072272 patent/WO2019034753A1/en not_active Ceased
- 2018-08-16 CA CA3072296A patent/CA3072296A1/en active Pending
- 2018-08-16 CN CN201880051751.2A patent/CN111032086B/zh active Active
- 2018-08-16 US US16/638,205 patent/US11236173B2/en active Active
- 2018-08-16 EP EP18756417.4A patent/EP3668543A1/en active Pending
-
2022
- 2022-01-18 US US17/578,014 patent/US12162949B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533726A5 (https=) | ||
| JP2021515568A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| JP2021516975A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| JP2020533965A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| JPWO2019175226A5 (https=) | ||
| JPWO2019175215A5 (https=) | ||
| JPWO2019175223A5 (https=) | ||
| JPWO2019175224A5 (https=) | ||
| JPWO2019175217A5 (https=) | ||
| JPWO2019175222A5 (https=) | ||
| JPWO2019175220A5 (https=) | ||
| JPWO2019175216A5 (https=) | ||
| JP2020515247A5 (https=) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2020531003A5 (https=) | ||
| JP2018510636A5 (https=) |